Author’s response to reviews

Title: Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study

Authors:

Medardo M Avila-Vazquez (medarav@mater.fcm.unc.edu.ar)
Roque R Maffrand (rmaffrand@uolsinectis.com.ar)
Mirta M Sosa (mirtasosa@hotmail.com)
Maria MA Franco (mariaangped@hotmail.com)
Beatriz MB Vaca de Alvarez (vacamb@onenet.com.ar)
Maria ML Cafferata (cafferaml@adinet.com.uy)
Eduardo E Bergel (bergel@allstat.org)

Version: 6 Date: 2 August 2004

Author’s response to reviews:

Dear Matt Hodgkinson,

MS: 1764316756276568

We are very grateful for the helpful reports on our submitted paper. We have made a major revision of our manuscript in the light of the comments of the editors and the three reviewers. Because all sections of the paper and the tables were rewritten, we are not including a version of the manuscript with changes highlighted. Please find below a description of the changes.

Mayor changes:

1. The title was changed according to the editor’s suggestion to “Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study”.

2. All sections of the article were rewritten to improve the quality of written English.

3. As suggested by Dr. Fielder we have shortened the introduction and discussion section. The text now does not include a detailed explanation of ROP pathogenesis.

4. We remove the sentence stating that ROP is avoidable, rewritten the section on ROP treatment, and provide more details on what are the signs of high risk ROP, as suggested by Dr Good.

5. As suggested by the reviewers, we have stressed in the discussion and conclusions the fact that this is a preliminary report, and that because of the weakness of the study design the results should be interpreted with caution.

6. Dr Coats express concerns regarding the differences between groups. We explore in more detail the differences between the control and ketorolac group, and now provide p-values to test if there are variables that are statistically different between groups at baseline (table 1). There was a clinical and statistically significant difference in duration of oxygen therapy. Additional details regarding this variable, and the adjustment of the effect of ketorolac on ROP is now provided.

7. To simplify the presentation of the results, figure 1 was replaced by table 2.

8. In table 1, death newborns are presented as the number "Dead before discharge" rather than the number that survived at discharge.

9. For consistency, and to simplify the interpretation of the results, we are now presenting the results using relative risks and relative risk reductions rather than odds ratios.
Minor changes

10. Removal the header and footer throughout the manuscript.
11. Removal the comment "Title Page"
12. Link of authors to their affiliation by the use of superscript numbers.
13. Removal of qualifications of authors.
14. Qualifications, e.g. MD from the title page were removed.
15. Change in abstract: objective -> Background; conclusion -> Conclusions
16. Removal of all text shading throughout the manuscript.
17. Change of nsad x NSAIDS in all manuscript.
18. We included a section heading Background.
19. The references are now cited in the text using consecutive numbers in square brackets. The reference list is now in the journal style.
21. Removal of section: Implications for research and Implications for practice and they were included in the text.
22. Competing interest: "None".
23. The tables style were changed according to the editorial requirements.
24. The corresponding author's email and the affiliation of EB were changed.

We hope that the new version of the paper is acceptable to you.

Yours sincerely,

Medardo Avila-Vazquez

Eduardo Bergel